YERVOY (Bristol-Myers Squibb Australia Pty Ltd)
Product name
YERVOY
Date registered
Evaluation commenced
Decision date
Approval time
170 working days (255)
Active ingredients
Ipilimumab
Registration type
EOI
Indication
YERVOY (IV infusion vial) in combination with OPDIVO (nivolumab), is now also indicated for the treatment of patients with unresectable or metastatic melanoma.
YERVOY, in combination with OPDIVO (nivolumab), is now also indicated for the treatment of patients with intermediate/poor-risk, previously untreated advanced renal cell carcinoma.